EGFR and non-small cell lung carcinoma: Also, first-generation EGFR-TKI treatment significantly reduced the risk of death in these patients with stage III NSCLC (HR, 0.34; 95% CI, 0.18–0.63, P = 0.001, Fig. 3D), when we excluded the ADAURA trial.